Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.
Last updated June 20, 2024
Status:
Concluded with an LOI
Manufacturer:
Sandoz Canada Inc.
Indication:
Multiple Indications
Last updated June 19, 2024
Status:
Concluded without agreement
Manufacturer:
Arcutis Biotherapeutics, Inc.
Indication:
Plaque psoriasis
Last updated June 14, 2024
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Primary hyperlipidemia and mixed dyslipidemia
Last updated June 3, 2024
Wyost (denosumab 120 mg/1.7 mL)
Status:
Concluded with an LOI
Manufacturer:
Sandoz Canada Inc.
Indication:
Multiple Indications
Last updated May 24, 2024
Status:
Concluded with an LOI
Manufacturer:
Sandoz Canada Inc.
Indication:
Multiple Indications
Last updated May 24, 2024
Status:
Concluded without agreement
Manufacturer:
ViiV Healthcare
Indication:
HIV-1 infection, in combination with other antiretroviral agents, in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations
Last updated May 22, 2024
Maviret (glecaprevir/pibrentasvir granules)
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Chronic Hepatitis C (Pediatric)
Last updated May 23, 2024
Status:
Concluded without agreement
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Metastatic Pancreatic Cancer
Last updated May 16, 2024
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
COVID-19
Last updated May 10, 2024